PCI – 7th June 2024
Thermofisher: Thu 29 February 2024, 11:15

Current Edition

Cell and Gene Therapy

Upcoming Events

SLAS Europe – 7th April 2025
PEGS Boston – 17/02/2025
Biotechnology Show 2025: 20th January 2025

Advertisement

Fujifilm rectangle: Fri 22 November 2024, 14:23
Roald Dahl Charity: Fri 15 November 2024, 12:57
A&M STABTEST: Fri 21 June 2024, 11:43
CDD Vault – 18.03.2025
Biopharma Group – 19th March 2025

The Cell Therapy Supply Chain and Risk Assessment Considerations

Across the world, patients who once may have had little hope of survival are benefiting from the treatment efficacy and potentially curative potential of novel cell therapies, advancing industry growth in this innovative and highly specialist area. These powerful ‘living drugs’ are by their very nature complex to produce and the manufacturing expertise required cannot be underestimated. While some general principles can be applied to the development of cell therapy treatments, it is important to consider, says Rachel Griffiths at PCI, that each product presents its own specific challenges and complexities for managing its generation, manufacture and delivery to the patient.

[wonderplugin_pdf src=”https://www.biopharmaceuticalmedia.com/wp-content/uploads/2018/12/The-cell-therapy-supply-chain-and-risk.pdf” width=”100%” height=”900px” style=”border:0;”]

 

 

Newcells 3 June 2024, 15:12
Aldevron: 16th January 2025
Richter: Wed 23 October 2024, 09:03
Tosoh – 29.04.25
Eppendorf – 18.03.2025
Asychem – 10.04.2025
Taconic Biosciences – 29.04.25
Steribar – 12.05.2025